IXI
NEUTRALIXICO Grants Share Options to Executives
The medical imaging analytics company IXICO has granted share options to its Chief Technology Officer, Chief Business Officer and VP Global Business Development.
IXICO
10.15GBX
0.00%
Market Cap
9.41M
Volume
2k
3% of avg
P/E Ratio
-0.05
EPS (TTM)
-2.1
Beta
0.66
Day Range
10.20p - 10.20p
52 Week Range
6.60p10.15p15.00p
10.15p
Upcoming Events
Q4 2025
Expected completion of full year 2025 financial period
High Impact Event
Q1 2026
Anticipated release of full year 2025 results
High Impact Event
IXI
VERY GOODIXICO Assists in FDA Clearance of New Alzheimer's Diagnostic Biomarker
The healthcare technology company has assisted in the FDA clearance of a new blood-based test that will help advance diagnosis and drug development in Alzheimer's disease.
IXI
NEUTRALIXICO Announces Holding Change
The healthcare data analytics company has announced a change in shareholding, with no further details provided.
IXI
NEUTRALIXICO Reports 26% Revenue Growth in Half-Year Results
The neuroscience imaging and biomarker analytics firm reported a 26% increase in revenue and improved gross margins, while still operating at a loss. New contracts and diversification efforts show promise.
IXI
NEUTRALIXICO Announces Change in Shareholder
The healthcare company announces a change in the investment manager and name of one of its shareholders, with no impact on its own operations.
IXI
NEUTRALIXICO Provides Update on Interim Results and Investor Presentation
The healthcare technology company will release its interim results and host an investor presentation next month.
IXI
VERY GOODIXICO Delivers Strong First Half Performance
The medical imaging analytics company reports robust first-half performance, with revenues up 26% and improved profitability, positioning it well for the remainder of the year.
IXI
GOODIXICO Secures New Contracts in Alzheimer's and Huntington's Disease
The healthcare data analytics firm has secured new contracts worth over £0.5 million to provide imaging services for Alzheimer's and Huntington's disease research, highlighting its market-leading position.
IXI
GOODIXICO's AI Imaging Platform Validated by Huntington's Disease Consortium
The healthcare company has made significant progress in validating its AI imaging platform for Huntington's Disease, generating new insights and positioning its technology for increased commercial adoption.
IXI
NEUTRALIXICO Grants Share Options to Executives
The healthcare technology company has granted share options to its top executives, with shareholder approval.